Synthaverse SA
SVE
Company Profile
Business description
Synthaverse SA is a global pharmaceutical company. Its goal is to provide the best, innovative and unique solutions for medicine. Its work is based on scientific and health knowledge. Along with its expert approach, it allows the company to create reliable and unique products. It manufactures one of the few drugs used internationally in the oncological immunotherapy of bladder cancer.
Contact
10, Uniwersytecka street
Lublin20-029
POLT: +48 815338221
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
237
Stocks News & Analysis
stocks
We lift our fair value estimate for this ASX energy play
Strong oil and LNG prices are a major win, though we don’t think they will stay high in the long term.
stocks
Chart of the Week: Headwinds for Aussie banks point to an imminent slowdown
Investor demand is expected to fade and slow credit growth as borrowers face higher costs and reduced tax breaks.
stocks
Hostile takeover on the cards for this ASX income opportunity
IFM lobs reasonable takeover offer.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,915.70 | 16.00 | 0.18% |
| CAC 40 | 8,072.13 | 31.96 | -0.39% |
| DAX 40 | 23,954.56 | 63.70 | -0.27% |
| Dow JONES (US) | 48,861.81 | 280.12 | -0.57% |
| FTSE 100 | 10,213.11 | 119.68 | -1.16% |
| HKSE | 26,111.84 | 432.06 | 1.68% |
| NASDAQ | 24,673.24 | 9.44 | 0.04% |
| Nikkei 225 | 59,917.46 | 619.90 | -1.02% |
| NZX 50 Index | 12,770.30 | 5.90 | 0.05% |
| S&P 500 | 7,135.95 | 2.85 | -0.04% |
| S&P/ASX 200 | 8,687.00 | 9.40 | 0.11% |
| SSE Composite Index | 4,107.51 | 28.88 | 0.71% |